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Abstract
Introduction: The risk of poor vaccine immunogenicity and more severe influenza disease in HIV necessitate strategies to
improve vaccine efficacy.
Methods: A randomized, multi-centered, controlled, vaccine trial with three parallel groups was conducted at 12 CIHR
Canadian HIV Trials Network sites. Three dosing strategies were used in HIV infected adults (18 to 60 years): two standard
doses over 28 days, two double doses over 28 days and a single standard dose of influenza vaccine, administered prior to
the 2008 influenza season. A trivalent killed split non-adjuvanted influenza vaccine (Fluviral
TM) was used. Serum
hemagglutinin inhibition (HAI) activity for the three influenza strains in the vaccine was measured to assess
immunogenicity.
Results: 297 of 298 participants received at least one injection. Baseline CD4 (median 470 cells/mL) and HIV RNA (76% of
patients with viral load ,50 copies/mL) were similar between groups. 89% were on HAART. The overall immunogenicity of
influenza vaccine across time points and the three influenza strains assessed was poor (Range HAI $40=31–58%). Double
dose plus double dose booster slightly increased the proportion achieving HAI titre doubling from baseline for A/Brisbane
and B/Florida at weeks 4, 8 and 20 compared to standard vaccine dose. Increased immunogenicity with increased antigen
dose and booster dosing was most apparent in participants with unsuppressed HIV RNA at baseline. None of 8 serious
adverse events were thought to be immunization-related.
Conclusion: Even with increased antigen dose and booster dosing, non-adjuvanted influenza vaccine immunogenicity is
poor in HIV infected individuals. Alternative influenza vaccines are required in this hyporesponsive population.
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Introduction
HIV infection is associated with deficiencies in both humoral and
cell-mediated immunity, which can alter the course of common
infectionsandinfluencevaccineimmunogenicity.[1],[2,3,4,5]While
highlyactiveantiretroviraltherapy(HAART)partiallyrestoresthese
deficiencies, HIV-infected persons remain at increased risk for
morbidityfrominfectiousdiseases,especiallyiftheabilitytogenerate
antigen-specific responses remains impaired.[6]
HIV infection predisposes individuals to increased susceptibility
to influenza, prolonged viral replication and shedding, longer
duration of influenza symptoms and higher influenza-related
mortality.[3,7,8,9] The risk for influenza-related death is estimated
to be 9.4–14.6 per 10,000 in persons with AIDS, compared with
0.09–0.10 per 10,000 among healthy adults aged 25 to 54 years
and 6.4–7.0 per 10,000 among the elderly.[10] In another study,
the risk for cardiopulmonary hospitalizations among women with
HIV infection was higher during influenza seasons.[11]
Controlled trials of single dose inactivated influenza vaccine in
HIV-infected adults conducted both in the pre- and post-HAART
eras have demonstrated safety but suboptimal antibody re-
sponse.[2,3][12,13] The likelihood of achieving seroprotective
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disease.[7,14,15] Vaccine immunogenicity is better in HIV
seropositive persons with minimal or no AIDS-related symptoms
and high CD4 counts.[14,15,16,17],[18] However, even in
antiretroviral treated HIV patients with high influenza vaccination
rates, protection from influenza disease is deficient.[19] Although
the use of booster dosing and increased vaccine antigen dose have
been assessed in the past, the results are conflicting, based on pre-
HAART populations and limited by small sample size.[14,20]
Definitive studies of alternative influenza vaccination strategies
in this population are required. To this end, we evaluated the
efficacy of increased vaccine antigen dose and the administration
of a vaccine booster dose in a representative HIV study
population.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1,
Flowchart S1, and Protocol S1.
Population and Setting
A randomized, multi-centered, controlled, vaccine study with
three parallel groups was conducted. HIV-infected volunteers, in
otherwise stable health, aged 18 to 60 years, were recruited at
twelve Canadian Institutes of Health Research Canadian HIV
Clinical Trials Network sites located across Canada (see
Acknowledgements for list of contributing sites). Enrolment began
following research ethics approval obtained at each individual site.
Informed, written consent was obtained from each participant.
Exclusion criteria included: receipt or anticipated requirement of
blood products, vaccine, or immunoglobulin preparation within
one month of study vaccine administration until completion of
study, use of immunosuppressive therapy or immune modulators,
dialysis, autoimmune disease, alcohol consumption $4 drinks per
day, history of cancer with the exception of cutaneous cancers
including Kaposi Sarcoma, basal cell carcinoma and non-invasive
HPV-related malignancy, known or suspected hypersensitivity to
any component of the study vaccines, including chicken eggs or
egg products and Thimerosol, history of immediate hypersensi-
tivity reaction and/or reaction resulting in neurological symptoms
to a previous dose of any influenza vaccine, or presentation with or
any recent history (within 24 hours) of any febrile illness (.38uC)
or symptoms of significant local or systemic infection. There were
no exclusion criteria for antiretroviral use, HIV viral load or CD4
T lymphocyte count.
Vaccine, Dosing and Immunogenicity Testing
The vaccine used was the 2008 seasonal trivalent killed split
non-adjuvanted influenza vaccine (Fluviral
TM, GSK, Laval,
Canada) containing A/Brisbane/59/2007 (H1N1), A/Uruguay/
716/2007 (H3N2), and B/Florida/4/2006. Subjects recruited at
each site were centrally randomized by the Canadian HIV Trials
Network to one of three groups. Participants and all study staff
were blinded to allocation, except for the individual who prepared
the vaccine who had no direct contact with study participants.
Group 1 received one adult dose of influenza vaccine (0.5 mL or
15 mg HA) between October 1st and November 15th 2008,
followed by a booster influenza vaccine administered 28 days later.
Group 2 received one double dose of influenza vaccine (1.0 mL or
30 mg HA) during the same interval, followed by a booster double
dose of vaccine administered 28 days later. Group 3 received a
single adult dose (0.5 mL or 15 mg HA) of influenza vaccine.
Placebo injections were not utilized in this study. Randomization
was stratified by CD4 T lymphocyte count (,200 cells/mL versus
$200 cells/mL).
Blood samples were centrifuged and the sera from each were
aliquoted into vials (minimum 2.0 ml/vial) for frozen storage at
280uC. Once all study specimens were collected, three sets of
aliquots of each serum sample were transported frozen to the
laboratory (GB) for hemagglutination inhibition (HAI) titre
evaluation. HAI titres were measured according to WHO
standard protocol.[21] Briefly, non-specific inhibitors were
removed from serum by overnight treatment with receptor
destroying enzyme (Denka Seiken, Tokyo, Japan). Physiologic
saline solution was then added to achieve a 1:10 dilution, followed
by incubation with packed guinea pig red blood cells (GRBC)
(Lampire Biological Laboratories Inc., Pipersville, PA) at 4uC for
60 min to remove non-specific agglutinins. Treated serum was
serially diluted in 25 ml of PBS and then mixed with an equal
volume of PBS containing 4 hemagglutinin units of A/Brisbane/
59/2007 (H1N1), A/Uruguay/716/2007 (H3N2) or B/Florida/
4/2006 viruses. After 30 min of incubation at room temperature,
50 ml of 1% GRBC solution was added to the mixture and
incubated for 45–60 min before evaluation of hemagglutination.
The HAI titer was recorded as the reciprocal of the last dilution
that inhibited hemagglutination.
Flu-like Illness
All subjects developing febrile respiratory syndromes during the
20-week period following initial influenza vaccination were asked
to report to clinic for assessment. A respiratory illness symptom
diary was also provided to capture events. Respiratory infections
were defined as a temperature .38.0uC associated with any one
or more of the following clinical symptoms: feverishness/chills;
cough; tachypnea/dyspnea; wheezing/stridor; rhinorrhea; sore
throat; myalgias. An in-house real-time multiplex reverse-tran-
scriptase PCR assay was utilized to identify influenza in those who
presented while symptomatic.[22]
Adverse Events
All subjects were observed at the site clinic for 15 minutes
following each study vaccination to monitor for anaphylactic
reactions, as well as for any other local and/or systemic reactions,
to the vaccine. Subjects were then provided with, and instructed
how to use, a thermometer, a transparent ruler and a diary to
continue to monitor for any local and/or systemic reactions to the
vaccine for 7 days following the study vaccination. Subjects were
asked to record their temperature (uC), any redness or swelling at
or near the injection site (mm), the severity of symptoms: pain (at
or near the injection site), malaise, headache, fatigue (none, mild,
moderate, severe), and any other adverse events. They were also
asked to contact the clinic if they were experiencing a fever. A new
diary was provided at each study visit to record any events that
occurred during the time before the next visit.
Statistical Analysis
The primary objective was to compare the immunogenicity of
each of the two novel vaccination strategies with the traditional
strategy of a single standard dose for each of the three influenza
strains. The proportion of subjects achieving doubling of HAI titre
from baseline at week 8 was selected as the primary outcome given
the anticipated potential for diminished immunogenicity in this
vaccine hyporesponsive population. Sample size calculations for
this study were based on the comparison of two independent
proportions using a two-tailed a of 0.05 and a (1-b) of 0.90. The
control rate of doubling of titres was estimated to be 50%, and it
was hypothesized that the modified doses of vaccine would
Influenza Vaccine Dosing Strategies in HIV
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improvement of 25%.
As recommended by the Committee for Proprietary Medicinal
Products (CPMP) [23], the proportion achieving seroconversion
(quadrupling of HAI titre from baseline) and seroprotection (HAI
titre $40 and $80 in those with baseline HAI titres #10) were
assessed and compared by randomized group at weeks 4, 8, and
20. These benchmarks are associated with high level protection
from clinical illness resulting from influenza infection. Serocon-
version proportions over 40% and seroprotection titres $40 in
70% of recipients are standard targets required for approval of
seasonal influenza vaccines. Geometric mean titres (GMT) at these
time points and geometric mean ratios (GMR) with baseline were
calculated and compared between groups. As per protocol, two
pair wise comparisons were conducted for each outcome: 1) single
dose plus booster versus single dose only, and 2) double dose plus
booster versus single dose only. Proportions were compared using
chi-square tests and GMT by t-tests. Missing values were imputed
for week 8 outcomes only as follows: if an outcome, e.g. doubling
of titres from baseline, was positive at weeks 4 and 20, it was
considered to be positive at week 8 as well. Otherwise, missing
responses were considered to be negative outcomes.
Multivariable logistic regression was used to explore the effects
of key potential predictors of immunogenicity outcomes. For each
outcome, all variables with p-values ,0.15 in individual models
controlling for treatment group were entered into multivariable
regression models.
Secondary outcomes included self-reported influenza-like illness
and PCR-confirmed influenza A and B identified from nasopha-
ryngeal swab. The original plan was to compare proportions
between groups as for the titre outcomes, but since the number of
events was unexpectedly small, simple descriptions were used
instead. All analyses were done using SAS (Statistical Analysis
Software), Version 9.1.3.
Results
Study Population and Disposition
Baseline characteristics were well balanced between groups
(Table 1). The mean age was 47 (SD 8.5) years. The majority were
male and on HAART with HIV RNA levels below detection (,50
copies/mL). The baseline median CD4 T lymphocyte count was
470 cells/mL. Despite a high proportion having been vaccinated
the previous year (84%), most participants (A/Brisbane: 67%, A/
Uruguay: 72%, B/Florida: 56%) had HAI titres # 10 at baseline.
Two hundred and ninety-eight participants were randomized,
297 received the first vaccination at baseline, and 281 returned for
the follow-up visit 28 days (+/2 8 days) later. HAI titre
measurements were unavailable for 6% of patients at week 4
and 9% at weeks 8 and 20. The distribution of missing values was
balanced across treatment groups. For those missing week 8 titre
values, a positive primary outcome was imputed for 4 of 25
patients missing A/Brisbane strain data, 2 of 16 patients missing
A/Uruguay strain results, and 6 of 29 patients without B/Florida
strain titres.
Vaccine Immunogenicity
Overall Immunogenicity. Overall vaccine immunogenicity
was poor, even by less stringent doubling of titre criteria (Figure 1,
panel A, B, C). CPMP seroconversion criteria (i.e. quadrupling of
titres in .40% of recipients) was met only in double dose and
double dose booster recipients for A/Uruguay (Figure 2, panel A,
B). Seroprotection (i.e. HAI titres $40 in .70% of recipients) was
not achieved with any of the three strategies evaluated (Figure 3,
panel A, B). GMT criteria (i.e. $2.5-fold increase in GMT from
baseline) was only met for A/Uruguay at week 8 (standard dose
plus booster: 2.6, double dose plus booster: 2.9, standard dose:
2.4).
Booster Dosing. The effect of booster dosing was evaluated
at weeks 8 (4 weeks post booster) and 20 (16 weeks post booster).
The overall HAI titres achieved were disappointing. However,
some evidence of benefit with booster dosing was detected. The
administration of a double dose plus double dose booster increased
the proportion of those achieving a doubling of HAI titres from
baseline at week 8 for A/Brisbane (61% vs 44%, p=0.02) and B/
Florida (50% vs 35%, p=0.03) (Figure 1, panel B) and at week 20
(47% vs 31%, p=0.02) for A/Brisbane (Figure 1, panel C)
compared to recipients of a single standard vaccine dose.
Administration of a standard dose plus booster dose increased
the proportion of those achieving a doubling in HAI titres from
baseline for B/Florida at week 8 (50% vs 35%, p=0.04) (Figure 1,
panel B) and week 20 (38% vs 23%, p=0.03) (Figure 1, panel C)
compared to recipients of a standard dose of vaccine. The
direction of effect for A/Brisbane was similar but not statistically
significant at weeks 8 and 20 (Figure 1, panels B, C). Booster
dosing did not improve HAI titre doubling for A/Uruguay.
Administration of a double dose plus double dose booster
increased the proportion of those achieving seroconversion (4-
fold increase in HAI from baseline) for A/Brisbane at weeks 8
(37% vs 20%, p=0.01) (Figure 2, panel B) and 20 (26% vs 15%,
p=0.05) (Figure 2, panel C) compared to recipients of a
standard vaccine dose. Similar trends were noted for the other
two antigens. A standard dose booster did not increase the
proportion of those achieving seroconversion at weeks 8 or 20
compared to a single standard dose of vaccine without booster
( F i g u r e2 ,p a n e l sB ,C ) .
Seroprotection was assessed in those with baseline HAI titres
#10 (Figure 3). Although still low overall, the double dose plus
booster strategy consistently demonstrated trends toward im-
proved seroprotection at weeks 8 (Figure 3, panel B) and 20
(Figure 3, panel C) for all three antigens compared to a single
standard dose. This was also observed for high seroprotective HAI
titres ($80) at week 8 for A/Uruguay (27% vs 11%, p=0.02). A
standard dose followed by a standard dose booster did not
consistently improve these endpoint measures.
GMT and GMR were compared at weeks 8 and 20 to evaluate
the effect of booster dosing (data not shown). Although the
direction of effect consistently favored booster versus non-booster
dosing strategies for the A/Brisbane and A/Uruguay strains, this
was not statistically or clinically significant. The same was true for
double dose versus standard dose booster recipients. GMT and
GMR declined significantly irrespective of dosing strategy by week
20.
Increased Antigen Dose. Given the study design, the effect
of an increased dose of vaccine (30 mg of each antigen) could be
assessed and compared to standard dose (15 mg of each antigen) at
week 4. Although not statistically significant, a trend toward
increased HAI titre doubling was noted with A/Brisbane and B/
Florida (Figure 1, panels A, B, C). Seroconversion rates for A/
Brisbane at week 4 (Figure 2, panel A) were increased significantly
and similar trends were noted for the other antigens. Week 4
seroprotection (HAI titre $40) was assessed in those with baseline
HAI titres #10 (Figure 3, panel A). A trend favoring increased
antigen dose was noted for A/Brisbane and B/Florida but not A/
Uruguay (Figure 3, panel A). GMT titres were higher, although
not statistically significant, at week 4 in double dose recipients (A/
Brisbane: 32.9; A/Uruguay: 47.3; B/Florida: 32.0) compared to
single (combined data from Groups 1 and 3 for A/Brisbane: 26.5;
Influenza Vaccine Dosing Strategies in HIV
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respectively).
Sub-group Analysis of HIV RNA Non-Suppressed
Patients. As planned a priori, the possible differential
treatment effect for patients without HIV viral suppression was
explored by means of a sub-group analysis, examining the
differences in HAI titre doubling for the 72 patients with non-
suppressed HIV viral load in comparison to the 226 with viral load
suppression (Figure 4). Among HIV RNA non-suppressed
patients, double dose vaccine appeared to improve HAI titre
doubling at week 4 and booster dosing improved this measure at
weeks 8 and 20 for each antigen, although the differences were not
statistically significant. Similar trends were noted for sero-
protection and seroconversion (data not shown). This trend was
not apparent in those with HIV RNA suppression.
Predictors of Immunogenicity. Exploratory analyses were
conducted to evaluate for factors predictive of vaccine immu-
nogenicity. Multivariable logistical regression was controlled for
baseline variables related to HIV therapy, HIV viral load, CD4
count, age, sex, weight, tobacco use, viral hepatitis co-infection,
history of prior influenza vaccination, and lack of baseline influenza
seroprotection (HAI titres#10). Note that adjustment forimportant
prognostic factors had a minimal effect on estimates of treatment
magnitude. At week 8, double dose plus booster recipients (in
comparison with single standard dose recipients) were more likely to
achieve HAI doubling for A/Brisbane [OR=2.4 (1.3–4.4),
p,0.01] and B/Florida [1.9 (1.0–3.5), p=0.04] and
seroconversion for A/Brisbane [2.2 (1.1–4.3), p=0.03] as well as
week20seroconversionforA/Uruguay[2.2(1.1–4.7),p=0.03]and
A/Brisbane [2.1 (1.0–4.4), p=0.05]. Baseline HAI titre .1:10 was
highly predictive of seroprotection (both HAI titres $40 and $80)
at weeks 8 and 20 (all antigens), doubling of titres at week 8 (all
antigens), and doubling of titres at week 20 (A/Uruguay and B/
Florida).
Although several other isolated trends were noted with
individual antigens or at specific time points, no other consistent
immunogenicity predictors were identified. CD4 count was not
found to predict immunogenicity when controlled for by baseline
HIV RNA level and the other above-mentioned variables.
Influenza-Like Illness
Only 28 subjects reported flu-like symptoms during the period
of evaluation; these were evenly distributed across the three
groups. Six PCR-confirmed cases of influenza were documented
(A/Brisbane=2; A/not subtyped=2, B/not subtyped=2). All
recovered without complication.
Figure 1. Proportion of patients with doubling of HAI titres. The proportion of vaccine recipients with doubling of HAI titres are described at
week 4 (i.e. 4 weeks following the initial vaccination), week 8 (i.e. 8 weeks following the initial vaccination and 4 weeks following the booster dose in
groups 1 and 2), and week 20. The HAI titre response is described for each of the three antigens included in the administered vaccine (A/H3N2/
Uruguay, A/H1N1/Brisbane, B/Florida). Group 1 (single dose followed by single dose booster at week 4), Group 2 (double dose followed by double
dose booster at week 4) and Group 3 (single dose without booster at week 4) are depicted.
doi:10.1371/journal.pone.0017758.g001
Table 1. Baseline characteristics.
Standard Dose plus
Booster Double Dose plus Booster Single Standard Dose Overall
(n=100) (n=104) (n=94)
Male 88% 92% 90% 90%
White 79% 81% 83% 81%
Antiretroviral Therapy at Time of
Vaccination
92% 86% 88% 89%
HIV RNA
,50 copies/mL
79% 72% 77% 76%
CD4 Count
,200 cells/mL
10% 11% 7% 9%
Influenza Vaccine in the Previous Year 80% 85% 88% 84%
HCV Co-Infection 15% 12% 6% 11%
HBV Co-Infection 8% 4% 2% 5%
Current Smokers 47% 37% 44% 42%
doi:10.1371/journal.pone.0017758.t001
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Vaccinations were well tolerated without increased local
reactogenicity as a consequence of increased antigen dose or
booster dosing. None of the 8 serious adverse events reported were
immunization-related. No HIV-related serious adverse events or
HIV-related opportunistic infections were reported.
Discussion
This randomized clinical trial evaluated two potential means of
achieving improved immunogenicity in HIV seropositive individ-
uals: the administration a booster vaccine dose and the use of
increased antigen dose.[20] Current Centers for Disease Control
and Prevention guidelines do not recommend either practice.[24]
However, the studies on which these recommendations are based
were conducted in the pre-HAART era, evaluated small sample
sizes, were not randomized and did not assess clinical out-
comes.[18,25,26] We evaluated HIV patients representative of
most clinical settings in the developed world. Unfortunately, no
clear, uniform and clinically significant benefit was identified with
either immunization strategy.
The use of a booster dose in our analysis, either with standard
dose or double dose, slightly improved immunogenicity with two
of the three antigens evaluated compared to a single, standard
dose of vaccine. This was most clearly evident in those without
HIV RNA suppression at baseline (Figure 4). However, immuno-
genicity was suboptimal, irrespective of dosing strategy. Our work
suggests that booster dosing with conventional influenza vaccine
will not address the issue of poor immunogenicity in this vaccine
hyporesponsive population. Although compelling, we do not
believe that our results are robust enough to recommend booster
dosing in those without HIV RNA suppression.
There is little literature evaluating the efficacy of increased
influenza vaccine antigen dose in HIV infected patients. In a
sentinel work, Kroon et al evaluated the effect of double dose
immunization in a cohort of HIV infected patients and concluded
that this strategy was ineffective in augmenting antibody
response.[14] However, the comparison arm was not randomized,
the sample size was small, and the study was conducted in the pre-
HAART period. As such, the majority of participants were
profoundly immune compromised. Therefore, the results may not
be applicable to current HIV populations in the developed world.
The majority of our study population was on antiretroviral therapy
with virological suppression and CD4 counts well over 200 cells/
mL. Despite a small increase in immunogenicity with administra-
tion of a double dose, our analysis is consistent with the findings of
Kroon et al. Although higher antigen doses could be assessed,
widespread use of an increased antigen dose would create vaccine
supply issues. Therefore, the feasibility of this strategy is
questionable, even if demonstrated to be effective.
Overall, the rates of HAI protection achieved by these
strategies, assessed by various CPMP benchmarks of success
[23], were disappointingly low in proportion and relatively short-
lived. Even with a lower benchmark of immunogenicity (i.e. two
Figure 2. Proportion of patients achieving seroconversion (quadrupling of HAI titres). The proportion of vaccine recipients with a
quadrupling of HAI titres are described at week 4 (i.e. 4 weeks following the initial vaccination), week 8 (i.e. 8 weeks following the initial vaccination
and 4 weeks following the booster dose in groups 1 and 2), and week 20. The HAI titre response is described for each of the three antigens included
in the administered vaccine (A/H3N2/Uruguay, A/H1N1/Brisbane, B/Florida). Group 1 (single dose followed by single dose booster at week 4), Group 2
(double dose followed by double dose booster at week 4) and Group 3 (single dose without booster at week 4) are depicted.
doi:10.1371/journal.pone.0017758.g002
Figure 3. Patients with baseline HAI titres # 10: proportion achieving seroprotection (titres $40). The proportion of vaccine recipients
with baseline HAI titres #10 achieving seroprotection (titres $40) are described at week 4 (i.e. 4 weeks following the initial vaccination), week 8 (i.e. 8
weeks following the initial vaccination and 4 weeks following the booster dose in groups 1 and 2), and week 20. The HAI titre response is described
for each of the three antigens included in the administered vaccine (A/H3N2/Uruguay, A/H1N1/Brisbane, B/Florida). Group 1 (single dose followed by
single dose booster at week 4), Group 2 (double dose followed by double dose booster at week 4) and Group 3 (single dose without booster at week
4) are depicted.
doi:10.1371/journal.pone.0017758.g003
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speaks to the overall poor immunogenicity of influenza vaccine in
those with HIV infection. Our work suggests that although
increased antigen dosing may slightly increase immunogenicity
four weeks after immunization when utilizing conventional
vaccines, this increase is minimal. This finding is consistent with
a recently published pandemic HIN1 study of adult immune
competent individuals in which the use of increased vaccine dose
did not improve measures of vaccine efficacy.[27] Other strategies,
including the use of vaccine adjuvants, should be evaluated in an
effort to achieve more substantive and long-lived success without
the need for increased antigen dose.[28,29]
Several limitations are acknowledged. The small sample size
likely influenced our ability to fully evaluate the influence of
several key variables on the primary outcome measure. However,
this was the largest randomized controlled trial of influenza
vaccine immunogenicity in HIV patients ever conducted. Because
of the relatively low incidence of influenza in Canada during the
2008–2009 season, insufficient cases were detected to allow for
evaluation of the influences of booster dosing or increased vaccine
dose on burden of influenza infection. We did not collect data on
HIV RNA levels or CD4 T lymphocyte counts during the course
of the study. However, it was our judgment that the safety of
trivalent split non-adjuvanted influenza vaccine in the HIV
population was already well-established.[2,3,12,13] CPMP criteria
for immunogenicity have not been validated in those living with
HIV. However, it seemed reasonable to consider these well
accepted criteria for evaluating immunogenicity in addition to the
utilization of a lower HAI criteria (i.e. doubling of HAI titres).
Our work has demonstrated the safety of two alternate influenza
vaccine strategies in a HIV population including increased antigen
dose and the use of booster dosing. Although this study
demonstrated a slight benefit with increased antigen dose followed
by booster dosing in achieving and maintaining seroprotective
HAI titres in this immune compromised population, the gain was
minimal, inconsistent, and the overall immunogenicity was poor.
Other vaccine strategies, including the use of adjuvants, are
currently under evaluation.
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